Castle Biosciences Inc CSTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
-
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
-
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
-
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
-
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
-
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
-
Castle Biosciences Reports First Quarter 2026 Results
Trading Information
- Previous Close Price
- $23.90
- Day Range
- $23.25–24.69
- 52-Week Range
- $14.59–44.28
- Bid/Ask
- $22.95 / $24.51
- Shares Outstanding
- 30.33M
- Market Cap
- $743.39M
- Volume/Avg
- 326,187 / 395,824
Key Statistics
- Price/Earnings (Normalized)
- 58.69
- Price/Sales
- 2.06
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 942
Valuation
|
Metric
|
CSTL
|
|---|---|
Price/Earnings (Normalized) | 58.69 |
Price/Book Value | 1.57 |
Price/Sales | 2.06 |
Price/Cash Flow | 20.82 |
Price/Earnings
CSTL
Financial Strength
|
Metric
|
CSTL
|
|---|---|
Quick Ratio | 6.23 |
Current Ratio | 6.75 |
Interest Coverage | −141.24 |
Quick Ratio
CSTL
Profitability
|
Metric
|
CSTL
|
|---|---|
Return on Assets (Normalized) | 3.56% |
Return on Equity (Normalized) | 4.25% |
Return on Invested Capital (Normalized) | 2.33% |
Return on Assets
CSTL
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|@GM@H$^ | LOCK|k$& | $196B | |||
| Danaher Corp
DHR
| LOCK|!l&FtDf | LOCK|dvw | $142B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|H??D>dM | LOCK|Z$ | $44B | |||
| Agilent Technologies Inc
A
| LOCK|c#n<@QB | LOCK|C>@ | $37B | |||
| Waters Corp
WAT
| LOCK|V#@Dm! | LOCK|NL | $35B | |||
| IQVIA Holdings Inc
IQV
| LOCK|!z!c&> | LOCK|%@?! | $34B | |||
| Illumina Inc
ILMN
| LOCK|Rr$@kv | LOCK|M?G@X | $28B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|G#wkQF^z | LOCK|&<hrs | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|^@>my%x | LOCK|K#%$ | $23B | |||
| Quest Diagnostics Inc
DGX
| LOCK|kpzK&Zx | LOCK|%>Z<% | $23B |
United States